Jacobs Levy Equity Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Jacobs Levy Equity Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-15,260	Closed	-$197K	–	1122
2019 Q4	$197K	Buy	+15,260	New	+$141K	﹤0.01%	941
2018 Q4	–	Sell	-16,492	Closed	-$1.02M	–	1095
2018 Q3	$1.02M	Buy	16,492 +4,452	+37%	+$301K	0.01%	648
2018 Q2	$889K	Buy	+12,040	New	+$938K	0.01%	692
2018 Q1	–	Sell	-5,919	Closed	-$498K	–	1086
2017 Q4	$498K	Buy	+5,919	New	+$580K	0.01%	756

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jacobs Levy Equity Management's BLCM Position: Q1 2020 in Review

Jacobs Levy Equity Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2020, closing a stake of 15,260 shares — an estimated $197K sold.

Jacobs Levy Equity Management first reported a position in BLCM in Q4 2017 and held it in 4 quarters. The position peaked at $1.02M in Q3 2018. 29 funds tracked by Wall St. Rank hold BLCM as of Q1 2020.

Jacobs Levy Equity Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Jacobs Levy Equity Management sold 15,260 Bellicum Pharmaceuticals, Inc. shares in Q1 2020, an estimated $197K.
Jacobs Levy Equity Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2017 and held it in 4 quarters.
Jacobs Levy Equity Management's Bellicum Pharmaceuticals, Inc. position peaked at $1.02M in Q3 2018.
29 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2020, filed 15 May 2020.